Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y.
Miyakoshi J, et al. Among authors: masuda k.
Lung Cancer. 2024 Apr 6;191:107788. doi: 10.1016/j.lungcan.2024.107788. Online ahead of print.
Lung Cancer. 2024.
PMID: 38593478